Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement